Skip to main
SHC

Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health (SHC) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sotera Health is projected to achieve adjusted EBITDA growth at a compound annual rate of 5%-8% from 2024 through 2027, indicating a potential margin expansion of 50-150 basis points by 2027. The company anticipates generating nearly 100 basis points of adjusted EBITDA margin improvement in 2024, driven by a favorable mix shift toward higher-margin lab testing services within the Nelson Labs segment. Additionally, revenue from pharmaceutical sales has increased significantly since Sotera’s acquisition of Nelson Labs, now accounting for approximately one-third of total sales, which signals encouraging momentum in cross-selling initiatives and overall customer satisfaction.

Bears say

The analysis of Sotera Health reveals several fundamental reasons contributing to a negative outlook on the company's stock. Notably, adjusted EBITDA margins have decreased by approximately 180 basis points from 2021 to 2024, primarily due to inflation, overstaffing, and a shift in revenue mix within the Nelson Labs segment, particularly following the decline in higher-margin COVID-related testing volumes. Additionally, despite historical organic revenue growth averaging nearly 9.0%, the company has faced significant pressure on its top line from customer supply chain challenges, contributing to expectations of underperformance in specific segments, particularly advisory services, which is anticipated to further impact overall sales in 2025.

Sotera Health (SHC) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sotera Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sotera Health (SHC) Forecast

Analysts have given Sotera Health (SHC) a Buy based on their latest research and market trends.

According to 6 analysts, Sotera Health (SHC) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sotera Health (SHC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.